期刊文献+

文拉法辛缓释片与阿米替林治疗难治性抑郁症的临床研究 被引量:10

Comparison of venlafaxine and amitriptyline in the treatment of patients with refractory depression
下载PDF
导出
摘要 目的观察文拉法辛缓释片和阿米替林对难治性抑郁症的综合疗效和不良反应。方法将符合入组标准的103例患者随机分成文拉法辛组51例和阿米替林组52例。于治疗前和治疗第1、2、4、8周末采用汉密尔顿抑郁量表(HAMD)17项评定疾病严重程度和疗效,采用不良反应量表(TESS)评定药物不良反应,采用生活质量综合评定问卷(WHOQOL-100)评定生活质量。结果 (1)文拉法辛组痊愈16例,有效18例,无效17例,有效率65.48%;阿米替林组痊愈14例,有效19例,无效19例,有效率63.46%;两组间有效率比较差异无统计学意义(P>0.05)。(2)治疗1周时,文拉法辛组与阿米替林组之间HAMD总分的差异有统计学意义(P<0.01),但是在治疗8周末差异无统计学意义。(3)治疗8周末,文拉法辛组WHOQOL生活领域、心理领域、社会关系、环境因素因子分均高于阿米替林组,差异有统计学意义(P<0.01)。(4)在不良反应方面,睡眠障碍(文拉法辛组嗜睡4例,阿米替林组失眠、早醒8例)的发生率组间差异有统计学意义,但是均较轻微。结论与阿米替林相比,文拉法辛缓释片治疗难治性抑郁症起效快,疗效好,安全性好,且能显著改善患者的生存质量。 Objective To explore the efficacy and safety of venlafaxine sustained release tablets (venlafaxine -SR) and amitriptyline in the treatment of patients with refractory depression. Methods A total of 103 patients with refractory depression were randomly divided into venlafaxine- SR group (51 cases) and amitriptyline group (52 cases) for 8 - week treatment. Disease severity and efficacy was assessed with Hamilton Depression Scale (HAMD) , adverse effects with Treatment Emergent Symptom Scale (TESS) and quality of life with the WHO Quality of Life (WHOQOL) at the baseline, 1 st weekend, 2nd weekend, 4th weekend and 8th weekend. Results ( 1 ) Effective rate in venlafaxine - SR group was 65.48% (recovery: 16 cases; effectiveness: 18 cases; inefficiency: 17 cases), in amitriptyline group was 63.46% (recovery: 14 cases; effectiveness: 19 cases; inefficiency: 19 cases). There was no significant difference in effective rate between the two groups ( P 〉 0.05 ). ( 2 ) There was significant difference in soere of HAMD between venlafaxine -SR group and amitriptyline group at the 1 st weekend (P 〈 0.01 ) , but the difference was not significant at the 8th weekend (P 〉 0.05). (3) At the 8th weekend, scores of the WHOQOL living domain, psychological domain, social relationship and environmental factor in venlafaxine - SR group were significantly higher than those in amitriptyline group (P 〈0.01 ). (4) There were significant differences in the incidence of insomnia between venlafaxine -SR group and amitriptyline group. But all the side effects were mild. Conclusion Compared with amitriptyline, Venlafaxine - SR is more effective and takes effect more quickly in the treatment of refractory depression with better tolerability. Furthermore, venlafaxine has advantage in improving quality of life of patients with refractory depression.
作者 周天红 孙凌
机构地区 天津市安定医院
出处 《精神医学杂志》 2011年第3期200-202,共3页 Journal of Psychiatry
关键词 难治性抑郁症 文拉法辛 阿米替林 生存质量 Refractory depression Venlafaxine Amitriptyline Quality of life
  • 相关文献

参考文献14

  • 1王祖訢.第三届国际难治性抑郁症会议概况[J].中华精神科杂志,1996,29(2):110-112. 被引量:8
  • 2Souery D, Papakostas GI, Trivedi MH. Treatment-resisrant depression[J]. J Clin Psychiatry,2006,67( Suppl 6) : 16-22.
  • 3汪向东 王希林 等.心理卫生评定量表手册(增订版)[J].中国心理卫生杂志,1999,:31-130.
  • 4Bonomi AE, Patrick DL, Bushnell DM, et al. Validation of the uniter states "version of the world health organization quality of life (WHOQOL) instrument [ J ]. J Clin Epidemiol, 2000,53 (1):1-12.
  • 5Marcelo T Berlim, Gustavo Turecki. Definition, Assessment, and Staging of Treatment Resistant Refractory Major Depression:A Re, view of Current Concepts and Methods [ J ]. Can J Psychiatry, 2007,52:46-49.
  • 6Fuchs S, Reggers J, Ansseau M. Guidelines for the treatment of depression[ J]. Rev Med Liege ,2000,55 (5) :389-394.
  • 7Fountoulakis KN, Kantartzis S, Siarnouli M, et al. Peripheral thyroid dysfunction in depression [ J ]. World J Biol Psychiatry, 2006,7(3) :131-137.
  • 8康瑞,朱少魁.文拉法辛缓释剂与SSRTs治疗难治性抑郁症对照研究[J].临床心身疾病杂志,2007,13(2):135-137. 被引量:8
  • 9翟书涛.难治性抑郁症的治疗(上)[J].临床精神医学杂志,2001,11(5):301-303. 被引量:80
  • 10Mark Z, Lwona C, Wilson M. Major depression disorder and axis I diagnostic comorbidity [ J ]. J Clin Psychiatry, 2002,63 : 187-193.

二级参考文献17

  • 1袁勇贵,张石宁.文拉法辛对选择性5-羟色胺再摄取抑制剂治疗无效的抑郁症患者的疗效[J].中华精神科杂志,2005,38(1):27-29. 被引量:37
  • 2金卫东.数理精神医学:(三)Meta分析[J].四川精神卫生,1996,9(1):62-63. 被引量:26
  • 3Entsuah A R, Huang H, Thase M E. Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors or placebo[J]. J Clin Psychiatry, 2001,62(11):869-877.
  • 4Thase M E. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors[J]. Bri J Psychiatry, 2001,178(3):234-241.
  • 5Stahl S M, Entsuah R, Rudolph R L. Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression[J]. Biol Psychiatry, 2002,52(12):1 166-1 174.
  • 6Rudolph R L, Entsuah R, Chitra R. A meta-analysis of the effects of venlafaxine on anxiety associated with depression[J]. J Clin Psychopharmacol, 1998,18(2):136-144.
  • 7Entsuah A R, Rudolph R L, Chitra R.Effectiveness of venlafaxine treatment in a broad spectrum of depressed patients: a meta-analysis[J]. Psychopharmacol Bull, 1995,31(4):759-766.
  • 8Thase M E. Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3 744 depressed patients[J]. J Clin Psychiatry, 1998,59(10):502-508.
  • 9中华医学会精神科分会.中国精神障碍分类与诊断标准[M](第3版)(CCMD-3)[M].济南:山东科学技术出版社,2001.75-78.
  • 10Word Realm Organization WHoQol~Brefin production administration scoring and generic version of the assessment,field trial version[J].Programme on Mental Realm.WHO:Geneva,1996:1

共引文献702

同被引文献81

引证文献10

二级引证文献96

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部